Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) CMO Harold Bernstein sold 15,000 shares of the stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $26.22, for a total value of $393,300.00. Following the completion of the sale, the chief marketing officer owned 15,000 shares of the company’s stock, valued at $393,300. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Harold Bernstein also recently made the following trade(s):
- On Wednesday, April 1st, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $29.46, for a total value of $441,900.00.
- On Friday, March 20th, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $49.10, for a total value of $736,500.00.
- On Tuesday, March 10th, Harold Bernstein sold 30,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $50.45, for a total value of $1,513,500.00.
Maze Therapeutics Stock Performance
NASDAQ MAZE opened at $24.46 on Wednesday. The company has a market capitalization of $1.35 billion, a price-to-earnings ratio of -9.67 and a beta of 2.50. Maze Therapeutics, Inc. has a twelve month low of $9.41 and a twelve month high of $53.65. The stock has a fifty day simple moving average of $32.59 and a 200 day simple moving average of $37.87. The company has a quick ratio of 17.88, a current ratio of 17.88 and a debt-to-equity ratio of 0.11.
Key Stories Impacting Maze Therapeutics
Here are the key news stories impacting Maze Therapeutics this week:
- Neutral Sentiment: HC Wainwright still rates Maze Therapeutics as a Buy and maintains a $110 target, suggesting the firm remains constructive on the long-term story despite trimming near- and medium-term earnings estimates.
- Negative Sentiment: HC Wainwright cut Q2 2026 EPS estimates to a larger loss, reinforcing concerns that Maze may take longer to improve profitability than previously expected.
- Negative Sentiment: HC Wainwright also lowered Q3, Q4, FY2026, FY2027, FY2028, FY2029 and FY2030 EPS forecasts, signaling a broader reduction in earnings expectations across the company’s growth horizon.
- Negative Sentiment: Recent insider selling by the CEO and CMO may be adding pressure on MAZE shares, as investors often view executive stock sales cautiously even when they occur under trading plans.
Institutional Investors Weigh In On Maze Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the business. Royal Bank of Canada raised its holdings in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after acquiring an additional 363 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Maze Therapeutics in the 4th quarter worth about $39,000. Ameritas Investment Partners Inc. raised its holdings in shares of Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after acquiring an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Maze Therapeutics in the 4th quarter worth about $43,000. Finally, Russell Investments Group Ltd. raised its holdings in shares of Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after acquiring an additional 1,725 shares during the last quarter.
Analysts Set New Price Targets
A number of brokerages have commented on MAZE. Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th. Wedbush upped their price target on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research report on Monday, March 16th. JPMorgan Chase & Co. upped their price target on shares of Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, March 31st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. Finally, Guggenheim upped their price target on shares of Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $66.00.
Check Out Our Latest Report on MAZE
Maze Therapeutics Company Profile
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Featured Stories
- Five stocks we like better than Maze Therapeutics
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
